Legal Opinion
Janssen Biotech, Inc. v. Celltrion Healthcare Co.
District Court, District of Columbia
Decided October 31, 2017No. C.A. No. 17–11008–MLWPublishedCited by 2 opinions
1Opinion of the Court
WOLF, D.J.
*339I. INTRODUCTION
Plaintiff Janssen Biotech, Inc. ("Janssen") alleges that defendants Celltrion Healthcare, Co., Ltd. and Celltrion, Inc. (together, "Celltrion"), and Hospira, Inc. ("Hospira") have infringed U.S. Patent No. 7,598,083 (the " '083 Patent"). Defendants have moved to dismiss for lack of standing. They claim that Janssen lacks standing because it is not the sole owner of the '083 Patent and the other co-owners have not joined Janssen as plaintiffs as required by Section 262 of the Patent Act, 35 U.S.C. § 262. See Ethicon, Inc. v. U.S. Surgical Corp., 135 F.3d 1456, 1467…
2Cases cited46 opinions
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Steel Co. v. Citizens for a Better EnvironmentSupreme Court of the United States · 1998
- New Hampshire v. MaineSupreme Court of the United States · 2001
- Robinson v. Shell Oil Co.Supreme Court of the United States · 1997
- Pegram v. HerdrichSupreme Court of the United States · 2000
41 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Valle v. Powertech Indus. Co.District Court, District of Columbia · 2019
- Valle v. Powertech Industrial Co. LtdDistrict Court, D. Massachusetts · 2019